Melanoma under 40
By Carole Renouf
17 November 2016
I spent a morning in clinic with one of MIA’s surgeons about a month ago. As each of her patients arrived, she inquired whether they would mind the CEO sitting in on their appointment because the CEO wanted to learn more about the experience of patients. Every single patient consented to having me present. They ranged from old to young, male to female, early to advanced melanoma and it was very moving for me to spend some time with them as they received everything from the worst news to the best. All the people with melanoma I met that day have stayed with me, but none more so than the young ones (under 40). It was the statistic that melanoma is the most common cancer in 15-39 year old Australians that really persuaded me to take this job.
A few years ago, when I was in a previous role, one of my proudest initiatives was the work we did reaching out to young women, those who got breast cancer in their 20s and 30s.
The impact of cancer on young lives is ferocious and wide-ranging. This is not to diminish in any way its significant impact on older lives, but when you are under 40 the experience of cancer tends to take more away across more aspects of your life and over a longer time. Also, as cancer services tend to be geared towards older people, you are likely to find less help and support suited to your needs and life stage.
The qualitative research that was done into breast cancer in young women revealed that the disease, diagnosis and treatment impacted issues as critical as future employment and career, finances, fertility, relationships and sexuality and self-image. If you would like to see footage from the press conference with affected young women, click here.
To my knowledge, no such research has yet been done in melanoma in Australia. Melanoma is the most common cause of cancer death in 20-39 year olds. In contrast to breast cancer, melanoma strikes both men and women (slightly more men) and therefore must assuredly involve additional issues to breast cancer. Yet, there is no body of evidence as to what these are, nor how to address them.
As we head towards 2017, I have set myself the goal of gathering the evidence from young Australians affected by melanoma of its impact on their lives and of any unmet needs they may have. This may mean a shift in the way we and others provide services.
For example, over 90% of melanoma – if caught early – is curable through surgery, so surgery remains a dominant treatment modality. A famous surgeon once said, “If you can’t cut it out, it’s not real” - yet studies show that psychosocial distress is very real in at least 30% of melanoma patients and I suspect even more real in the young. So is there an unmet need for more psychosocial support for under 40s affected by melanoma, for example?
If you’d like to share your experience and help me gather the evidence about the impact of melanoma on young Australians, please contact us at firstname.lastname@example.org for a personal interview. Your contribution would be greatly appreciated.
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.
It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.
Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.
Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.
It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.
They are a formidable team - in work and in play
This week, Melanoma Institute Australia hosted the first of six
Federal government urged
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!
Lauren O'Brien tells us why she's running for a cause close to her heart
MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in
An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a